Page last updated: 2024-12-08

3-methyleneindolenine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-methyleneindolenine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-methyleneindolenine : An indole that consists of 3H-indole bearing a methylene substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID170404
CHEBI ID63905
SCHEMBL ID5488008
MeSH IDM0256931

Synonyms (11)

Synonym
40642-83-9
3-methyleneindolenine
3-methylene-3h-indole
3-methylene-indolenine
3h-indole, 3-methylene-
CHEBI:63905
SCHEMBL5488008
3-methylidene-3h-indole
DTXSID00193643
3-methyleneindole
Q27132906

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" 3MI is bioactivated to toxic intermediates by cytochrome P450 enzymes."( Production and characterization of specific antibodies: utilization to predict organ- and species-selective pneumotoxicity of 3-methylindole.
Kaster, JK; Yost, GS, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
"In responding to Drs Calabrese and Baldwin's question, 'At what point, if ever, should hormesis be employed as the principal dose response default assumption in risk assessment?', we examined the benefits of replacing traditional dose-response with hormesis."( Examining the risks and benefits of replacing traditional dose-response with hormesis.
Oehme, FW; Pickrell, JA, 2005
)
0.33
"In examining traditional dose-response and hormesis, we have considered the case examples of pulmonary hyperplasia following inhalation of carbon black and pulmonary hyperplasia after methyleneindolenine (3MEIN) exposures, development of irreversible pulmonary fibrosis, effect of continuous exercise and low-level lead exposures, and colorectal cancer."( Examining the risks and benefits of considering both the traditional dose--response and hormesis in arriving at an acceptable exposure level.
Oehme, FW; Pickrell, JA, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (22.22)18.2507
2000's5 (55.56)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.30 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]